Position in ANIP
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$194,710
-$4,376 QoQ
Shares Held
2,532
+0.4% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANIP Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026MAI Capital Management holds $12,062,659 across 49 Drug Manufacturers - Specialty & Generic names. ANIP ranks #6 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
78,883 | $9,324,759 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
1,060 | $628,558 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
4,242 | $558,841 | |
| 4 | VTRS |
Viatris Inc
|
31,574 | $426,564 | |
| 5 | HLN |
Haleon plc
|
19,682 | $197,016 | |
| 6 | ANIP |
Ani Pharmaceuticals Inc
This page
|
2,532 | $194,710 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
9,014 | $125,294 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
3,235 | $106,981 |
All Filings in ANIP
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $194,710 | 2,532 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $199,086 | 2,522 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $229,000 | 2,500 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $163,125 | 2,500 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $167,375 | 2,500 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $138,200 | 2,500 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||